Sulfamerazine

• CAT Number: I001106
• CAS Number: 127-79-7
• Molecular Formula: C11H12N4O2S
• Molecular Weight: 264.3
• Purity: ≥95%
• Target: Antibacterial
• Solubility: DMSO 55 mg/mL
• Storage: 2-8°C
• IUPAC Name: 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
• InChI: InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
• InChIKey: QPPBRPIAZZHUNT-UHFFFAOYSA-N
• SMILES: CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N

Sulfamerazine (Cat No.:I001106) is a sulfonamide antibacterial agent. It belongs to the class of sulfonamide drugs, which are widely used for their antibacterial properties. Sulfamerazine acts by inhibiting the growth and reproduction of bacteria, particularly Gram-negative and some Gram-positive bacteria. By interfering with the synthesis of bacterial proteins, sulfamerazine disrupts essential cellular processes and effectively combats bacterial infections. It is commonly prescribed for the treatment of various bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. Sulfamerazine plays a crucial role in modern medicine as an effective antimicrobial agent.

Reference

1:Pipette-tip solid-phase extraction based on deep eutectic solvent modified graphene for the determination of sulfamerazine in river water. Liu L, Tang W, Tang B, Han D, Row KH, Zhu T.J Sep Sci. 2017 May;40(9):1887-1895. doi: 10.1002/jssc.201601436. Epub 2017 Apr 5. PMID: 28266787 2:The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems. Gniado K, Löbmann K, Rades T, Erxleben A.Int J Pharm. 2016 May 17;504(1-2):20-6. doi: 10.1016/j.ijpharm.2016.03.023. Epub 2016 Mar 16. PMID: 26992818 3:Correlating the chemical and spectroscopic characteristics of natural organic matter with the photodegradation of sulfamerazine. Batista AP, Teixeira AC, Cooper WJ, Cottrell BA.Water Res. 2016 Apr 15;93:20-9. doi: 10.1016/j.watres.2015.11.036. Epub 2015 Dec 2. PMID: 26878479 4:Synthesis of novel sulfonamide analogs containing sulfamerazine/sulfaguanidine and their biological activities. Aday B, Sola P, Çolak F, Kaya M.J Enzyme Inhib Med Chem. 2016 Dec;31(6):1005-10. doi: 10.3109/14756366.2015.1079183. Epub 2015 Aug 31. PMID: 26327456 5:Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics. Pallipurath AR, Skelton JM, Warren MR, Kamali N, McArdle P, Erxleben A.Mol Pharm. 2015 Oct 5;12(10):3735-48. doi: 10.1021/acs.molpharmaceut.5b00504. Epub 2015 Sep 8. PMID: 26317333 6:Solubility and release modulation effect of sulfamerazine ternary complexes with cyclodextrins and meglumine. Aloisio C, de Oliveira AG, Longhi M.J Pharm Biomed Anal. 2014 Nov;100:64-73. doi: 10.1016/j.jpba.2014.07.008. Epub 2014 Jul 30. PMID: 25129645 7:Effects of ball-milling and cryomilling on sulfamerazine polymorphs: a quantitative study. Macfhionnghaile P, Hu Y, Gniado K, Curran S, Mcardle P, Erxleben A.J Pharm Sci. 2014 Jun;103(6):1766-78. doi: 10.1002/jps.23978. Epub 2014 Apr 22. PMID: 24756899 8:Investigation of inclusion complexes of sulfamerazine with α- and β-cyclodextrins: an experimental and theoretical study. Rajendiran N, Mohandoss T, Venkatesh G.Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 24;124:441-50. doi: 10.1016/j.saa.2014.01.057. Epub 2014 Jan 21. PMID: 24508883 9:The influence of sodium salts (iodide, chloride and sulfate) on the formation efficiency of sulfamerazine nanocrystals. Lou H, Liu M, Qu W, Johnson J, Brunson E, Almoazen H.Pharm Dev Technol. 2014 Aug;19(5):548-55. doi: 10.3109/10837450.2013.805777. Epub 2013 Jun 13. PMID: 23763457 10:Characterization, inclusion mode, phase-solubility and in vitro release studies of inclusion binary complexes with cyclodextrins and meglumine using sulfamerazine as model drug. Aloisio C, Gomes de Oliveira A, Longhi M.Drug Dev Ind Pharm. 2014 Jul;40(7):919-28. doi: 10.3109/03639045.2013.790408. Epub 2013 Apr 29. PMID: 23627444